Table 1.
Baseline Characteristics of the Patients
Variable | 14-Day BQT (n=102) | 14-Day MIT (n=99) | p-value* | 14-Day CTT (n=581) |
---|---|---|---|---|
Age, yr | 56.6±11.1 | 56.7±11.3 | 0.905 | 55.3±12.6 |
Male sex | 41 (40.2) | 42 (42.9) | 0.703 | 332 (57.1) |
Mean BMI, kg/m2 | 24.3 | 24.6 | 0.263 | 25.4 |
Diabetes | 18/97 (18.6) | 18/97 (18.6) | >0.999 | 79/563 (14.0) |
Hypertension | 18/99 (18.2) | 14/97 (14.4) | 0.478 | 168/563 (29.8) |
History of peptic ulcer | 12 (11.7) | 13 (13.1) | 0.809 | 118/563 (20.9) |
Smoking | 11/89 (12.4) | 17/89 (19.1) | 0.051 | 153/479 (31.9) |
Alcohol | 17/76 (22.4) | 26/82 (31.7) | 0.247 | 230/479 (48.0) |
Diagnosis | 0.429 | |||
Gastritis | 51 (50.0) | 41 (41.4) | 244 (42.0) | |
Peptic ulcer | 46 (45.1) | 53 (53.5) | 302 (52.0) | |
Gastric cancer | 2 (2.0) | 1 (1.0) | 17 (2.9) | |
Gastric adenoma | 2 (2.0) | 4 (4.1) | 15 (2.6) | |
MALT lymphoma | 1 (0.9) | 0 | 3 (0.5) | |
Significant point mutation† | ||||
A2142G | 3 (2.9) | 3 (3.0) | >0.999 | |
A2143G | 95 (93.1) | 93 (93.9) | 0.290 | |
A2142C | 2 (2.1) | 1 (1.0) | 0.619 | |
A2143C | 2 (2.1) | 1 (1.0) | 0.621 | |
A2144G | 34 (35.1) | 36 (37.9) | 0.795 |
Data are presented as mean±SD, number (%), or number/number (%).
BQT, bismuth-based quadruple therapy; MIT, metronidazole-intensified triple therapy; CTT, clarithromycin-based triple therapy; BMI, body mass index; MALT, mucosa-associated lymphoid tissue.
*p-value indicates comparison between the BQT and MIT; †The sum of proportion is not 100% because of overlapping among point mutations.